MEA Nasal Spray Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Middle East and Africa nasal spray market is projected to register a CAGR of 5.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East and Africa Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (South Africa, Saudi Arabia, UAE, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa nasal spray market are:

Rise in the therapeutic application of the nasal spray

Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19

Market Players

Some of the major market players operating in the Middle East and Africa nasal spray market are:

EMERGENT

Cipla Inc.

Sandoz International GmbH (A Part of Novartis)

Aytu Health (A subsidiary of Aytu BioPharma, Inc.)

Bayer AG

GlaxoSmithKline plc.

Assertio Therapeutics, Inc.

Aurena Laboratories.

J Pharmaceuticals

St. Renatus.

Ultratech India Limited

Catalent, Inc.

Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)

Pfizer Inc.

Viatris Inc.

LEEFORD HEALTHCARE LTD

Aishwarya Group

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 26

2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCT TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

4.1 PORTER'S FIVE FORCES MODEL 42
4.2 PESTEL ANALYSIS 43

5 INDUSTRY INSIGHTS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 44

5.1 INDUSTRY INSIGHTS 44

6 REGULATIONS: MIDDLE EAST & AFRICA NASAL SPRAY MARKET 45

7 MARKET OVERVIEW 46

7.1 DRIVERS 48
- 7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 48
- 7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 48
- 7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 49
- 7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 50
7.2 RESTRAINTS 51
- 7.2.1 PRODUCT RECALLS 51
- 7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 52
7.3 OPPORTUNITIES 53
- 7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 53
- 7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 53
- 7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 54
7.4 CHALLENGES 54
- 7.4.1 REGULATORY HURDLES 54
- 7.4.2 ADDICTION TO NASAL SPRAY 55

8 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE 56

8.1 OVERVIEW 57
8.2 DECONGESTION NASAL SPRAY 60
8.3 STEROID NASAL SPRAY 61
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 62
8.5 OTHERS 63

9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN 64

9.1 OVERVIEW 65
9.2 PUMP BOTTLES 68
9.3 PRESSURIZED CANISTERS 69

10 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM 70

10.1 OVERVIEW 71
10.2 MULTI DOSE 74
10.3 UNIT/SINGLE DOSE 75
10.4 BI DOSE 76

11 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 78

11.1 OVERVIEW 79
11.2 ANTIHISTAMINE 82
11.3 NASAL STEROIDS 83
11.4 MAST CELL INHIBITOR 84
11.5 ANTICHOLINERGIC 85

12 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION 86

12.1 OVERVIEW 87
12.2 NASAL CONGESTION 90
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 91
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 92
12.5 VACCINATION 93
12.6 OTHERS 94

13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 95

13.1 OVERVIEW 96
13.2 PRESCRIBED 99
13.3 OVER THE COUNTER 100

14 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER 102

14.1 OVERVIEW 103
14.2 HOME CARE SETTINGS 106
14.3 HOSPITALS 107
14.4 CLINICS 108
14.5 COMMUNITY HEALTH CARE 109

15 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY REGION 110

15.1 MIDDLE EAST AND AFRICA 111
- 15.1.1 SOUTH AFRICA 118
- 15.1.2 UAE 120
- 15.1.3 SAUDI ARABIA 122
- 15.1.4 REST OF MIDDLE EAST & AFRICA 124

16 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 125

16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 125

17 SWOT ANALYSIS 126

18 COMPANY PROFILE 127

18.1 GLAXOSMITHKLINE PLC. 127
- 18.1.1 COMPANY SNAPSHOT 127
- 18.1.2 REVENUE ANALYSIS 127
- 18.1.3 COMPANY SHARE ANALYSIS 128
- 18.1.4 PRODUCT PORTFOLIO 128
- 18.1.5 RECENT DEVELOPMENTS 128
18.2 PFIZER INC. 130
- 18.2.1 COMPANY SNAPSHOT 130
- 18.2.2 REVENUE ANALYSIS 130
- 18.2.3 COMPANY SHARE ANALYSIS 131
- 18.2.4 PRODUCT PORTFOLIO 131
- 18.2.5 RECENT DEVELOPMENTS 131
18.3 EMERGENT 133
- 18.3.1 COMPANY SNAPSHOT 133
- 18.3.2 REVENUE ANALYSIS 133
- 18.3.3 COMPANY SHARE ANALYSIS 134
- 18.3.4 PRODUCT PORTFOLIO 134
- 18.3.5 RECENT DEVELOPMENT 134
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 135
- 18.4.1 COMPANY SNAPSHOT 135
- 18.4.2 REVENUE ANALYSIS 135
- 18.4.3 COMPANY SHARE ANALYSIS 136
- 18.4.4 PRODUCT PORTFOLIO 136
- 18.4.5 RECENT DEVELOPMENT 136
18.5 CATALENT, INC. 137
- 18.5.1 COMPANY SNAPSHOT 137
- 18.5.2 REVENUE ANALYSIS 137
- 18.5.3 COMPANY SHARE ANALYSIS 138
- 18.5.4 PRODUCT PORTFOLIO 138
- 18.5.5 RECENT DEVELOPMENTS 138
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 140
- 18.6.1 COMPANY SNAPSHOT 140
- 18.6.2 REVENUE ANALYSIS 140
- 18.6.3 PRODUCT PORTFOLIO 141
- 18.6.4 RECENT DEVELOPMENTS 141
18.7 AISHWARYA GROUP 142
- 18.7.1 COMPANY SNAPSHOT 142
- 18.7.2 PRODUCT PORTFOLIO 142
- 18.7.3 RECENT DEVELOPMENTS 142
18.8 ASSERTIO THERAPEUTICS, INC. 143
- 18.8.1 COMPANY SNAPSHOT 143
- 18.8.2 REVENUE ANALYSIS 143
- 18.8.3 PRODUCT PORTFOLIO 144
- 18.8.4 RECENT DEVELOPMENT 144
18.9 AURENA LABORATORIES. 145
- 18.9.1 COMPANY SNAPSHOT 145
- 18.9.2 PRODUCT PORTFOLIO 145
- 18.9.3 RECENT DEVELOPMENTS 145
18.10 BAYER AG 147
- 18.10.1 COMPANY SNAPSHOT 147
- 18.10.2 REVENUE ANALYSIS 147
- 18.10.3 COMPANY SHARE ANALYSIS 148
- 18.10.4 PRODUCT PORTFOLIO 148
- 18.10.5 RECENT DEVELOPMENTS 148
18.11 CIPLA INC. 150
- 18.11.1 COMPANY SNAPSHOT 150
- 18.11.2 REVENUE ANALYSIS 150
- 18.11.3 PRODUCT PORTFOLIO 151
- 18.11.4 RECENT DEVELOPMENT 151
18.12 J PHARMACEUTICALS. 152
- 18.12.1 COMPANY SNAPSHOT 152
- 18.12.2 PRODUCT PORTFOLIO 152
- 18.12.3 RECENT DEVELOPMENTS 152
18.13 LEEFORD HEALTHCARE LTD 153
- 18.13.1 COMPANY SNAPSHOT 153
- 18.13.2 PRODUCT PORTFOLIO 153
- 18.13.3 RECENT DEVELOPMENTS 153
18.14 ST. RENATUS. 154
- 18.14.1 COMPANY SNAPSHOT 154
- 18.14.2 PRODUCT PORTFOLIO 154
- 18.14.3 RECENT DEVELOPMENTS 154
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 155
- 18.15.1 COMPANY SNAPSHOT 155
- 18.15.2 REVENUE ANALYSIS 155
- 18.15.3 PRODUCT PORTFOLIO 156
- 18.15.4 RECENT DEVELOPMENTS 156
18.16 ULTRATECH INDIA LIMITED 157
- 18.16.1 COMPANY SNAPSHOT 157
- 18.16.2 PRODUCT PORTFOLIO 157
- 18.16.3 RECENT DEVELOPMENTS 157
18.17 VIATRIS INC. 158
- 18.17.1 COMPANY SNAPSHOT 158
- 18.17.2 REVENUE ANALYSIS 158
- 18.17.3 COMPANY SHARE ANALYSIS 159
- 18.17.4 PRODUCT PORTFOLIO 159
- 18.17.5 RECENT DEVELOPMENT 159

19 QUESTIONNAIRE 160

20 RELATED REPORTS 164

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 51
TABLE 2 MIDDLE EAST & AFRICA DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 53
TABLE 3 MIDDLE EAST & AFRICA STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 54
TABLE 4 MIDDLE EAST & AFRICA SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 5 MIDDLE EAST & AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 6 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 59
TABLE 7 MIDDLE EAST & AFRICA PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 8 MIDDLE EAST & AFRICA PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 65
TABLE 10 MIDDLE EAST & AFRICA MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 11 MIDDLE EAST & AFRICA UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 12 MIDDLE EAST & AFRICA BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 13 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 73
TABLE 14 MIDDLE EAST & AFRICA ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 15 MIDDLE EAST & AFRICA NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 MIDDLE EAST & AFRICA MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 17 MIDDLE EAST & AFRICA ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 18 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 81
TABLE 19 MIDDLE EAST & AFRICA NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 20 MIDDLE EAST & AFRICA ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 21 MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 22 MIDDLE EAST & AFRICA VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 24 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 90
TABLE 25 MIDDLE EAST & AFRICA PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 26 MIDDLE EAST & AFRICA OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 27 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 97
TABLE 28 MIDDLE EAST & AFRICA HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 30 MIDDLE EAST & AFRICA CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 31 MIDDLE EAST & AFRICA COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 32 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 108
TABLE 33 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 108
TABLE 34 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 108
TABLE 35 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 108
TABLE 36 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 109
TABLE 37 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 109
TABLE 38 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 109
TABLE 39 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 40 SOUTH AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110
TABLE 41 SOUTH AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 110
TABLE 42 SOUTH AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 110
TABLE 43 SOUTH AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 110
TABLE 44 SOUTH AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 111
TABLE 45 SOUTH AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 111
TABLE 46 SOUTH AFRICA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 111
TABLE 47 UAE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 112
TABLE 48 UAE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 112
TABLE 49 UAE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 112
TABLE 50 UAE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 112
TABLE 51 UAE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 113
TABLE 52 UAE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 113
TABLE 53 UAE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 113
TABLE 54 SAUDI ARABIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 55 SAUDI ARABIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 114
TABLE 56 SAUDI ARABIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 114
TABLE 57 SAUDI ARABIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 114
TABLE 58 SAUDI ARABIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 115
TABLE 59 SAUDI ARABIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 115
TABLE 60 SAUDI ARABIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 61 REST OF MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: SEGMENTATION 17
FIGURE 2 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: DATA TRIANGULATION 20
FIGURE 3 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: DROC ANALYSIS 21
FIGURE 4 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 22
FIGURE 5 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS 22
FIGURE 6 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS 24
FIGURE 7 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: DBMR MARKET POSITION GRID 25
FIGURE 8 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID 26
FIGURE 9 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS 27
FIGURE 10 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: SEGMENTATION 31
FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA NASAL SPRAY MARKET IN THE FORECAST PERIOD 32
FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA NASAL SPRAY MARKET IN 2023 AND 2030 32
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA NASAL SPRAY MARKET 38
FIGURE 14 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022 48
FIGURE 15 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 49
FIGURE 16 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 49
FIGURE 17 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 50
FIGURE 18 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022 56
FIGURE 19 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION) 57
FIGURE 20 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030) 57
FIGURE 21 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE 58
FIGURE 22 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY DOSAGE FORM, 2022 62
FIGURE 23 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION) 63
FIGURE 24 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030) 63
FIGURE 25 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE 64
FIGURE 26 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022 70
FIGURE 27 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION) 71
FIGURE 28 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030) 71
FIGURE 29 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE 72
FIGURE 30 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY APPLICATION, 2022 78
FIGURE 31 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 79
FIGURE 32 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030) 79
FIGURE 33 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE 80
FIGURE 34 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022 87
FIGURE 35 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION) 88
FIGURE 36 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030) 88
FIGURE 37 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE 89
FIGURE 38 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY END USER, 2022 94
FIGURE 39 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION) 95
FIGURE 40 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030) 95
FIGURE 41 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 42 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: SNAPSHOT (2022) 103
FIGURE 43 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY COUNTRY (2022) 105
FIGURE 44 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030) 105
FIGURE 45 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030) 106
FIGURE 46 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030) 106
FIGURE 47 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: COMPANY SHARE 2022 (%) 116